Trevi Therapeutics Inc (TRVI) Stock Analysis
Verdict: HOLD
Pivotal Phase 3 Haduvio trials offer multi-bagger potential backed by 318.9M USD cash, with trial outcome as the core binary risk.
Investment score: 62/100
Analysis as of
Is Trevi Therapeutics Inc stock worth reviewing? AI model thesis
The model score of 62/100 falls in the HOLD range. The central thesis and factor breakdown explain the assessment.
7-factor investment score
- Valuation: 55/100 (weight 20%)
- Financial Health: 85/100 (weight 15%)
- Technical Momentum: 48/100 (weight 15%)
- Earnings Quality: 60/100 (weight 15%)
- Insider Sentiment: 40/100 (weight 10%)
- Analyst Consensus: 85/100 (weight 10%)
- Risk-Adjusted Return: 62/100 (weight 15%)
Trevi Therapeutics Inc opportunities and risks
What speaks for TRVI
- Pivotal Phase 3 OCEAN-1/OCEAN-2 trial progression for Haduvio in IPF-related chronic cough.
What speaks against TRVI
- Binary clinical trial failure or inconclusive efficacy data for Haduvio.
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| TRVI | n/a | 0.0x | n/a | 0.0% | 0.0% | -1.9% |
| TRLV | n/a | 1.7x | 6.8x | 54.6% | -7.0% | 12.3% |
| HRMY | 12.6x | 2.4x | 6.8x | 75.4% | 18.9% | 15.6% |
| PBH | 13.0x | 2.0x | 13.4x | 53.3% | 15.6% | 10.6% |
| VRNO.NE | n/a | 0.5x | 5.1x | 45.8% | -30.7% | 10.2% |
| NKTR | n/a | 31.1x | n/a | 99.4% | -287.8% | -13.8% |
| Peer median | n/a | 2.0x | 6.8x | 54.6% | -7.0% | 10.6% |
Frequently asked questions about Trevi Therapeutics Inc (TRVI)
Is TRVI stock a good investment?
The cached TradeMates AI model rates Trevi Therapeutics Inc as HOLD with an investment score of 62/100. The model score of 62/100 falls in the HOLD range. The central thesis and factor breakdown explain the assessment. This is algorithmic model output, not personal investment advice.
Is TRVI stock a buy?
The TradeMates model verdict for TRVI is HOLD with an investment score of 62/100. Treat this as a model signal to review, not a personal buy recommendation.